

Adolfo DÃ- ez-PÃ©rez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1514956/publications.pdf>

Version: 2024-02-01

149
papers

9,086
citations

57681

46
h-index

49824

91
g-index

152
all docs

152
docs citations

152
times ranked

9899
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality, Falls, and Fracture Risk Are Positively Associated With Frailty: A SIDIAP Cohort Study of 890 000 Patients. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 148-154.	1.7	18
2	Associations between parameters of peripheral quantitative computed tomography and bone material strength index. <i>Bone</i> , 2022, 155, 116268.	1.4	3
3	Management of patients at very high risk of osteoporotic fractures through sequential treatments. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 695-714.	1.4	33
4	Development and external validation of a 1- and 5-year fracture prediction tool based on electronic medical records data: The EPIC risk algorithm. <i>Bone</i> , 2022, 162, 116469.	1.4	3
5	Impact microindentation in men with impaired fasting glucose and type 2 diabetes. <i>Bone</i> , 2021, 142, 115685.	1.4	21
6	Radiofrequency Echographic Multi Spectrometry (REMS) for the diagnosis of osteoporosis in a European multicenter clinical context. <i>Bone</i> , 2021, 143, 115786.	1.4	29
7	Hospital-at-Home Expands Hospital Capacity During COVID-19 Pandemic. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 939-942.	1.2	24
8	Functional Analyses of Four CYP1A1 Missense Mutations Present in Patients with Atypical Femoral Fractures. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7395.	1.8	6
9	Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1504.	3.8	38
10	Associations between Bone Material Strength Index, Calcaneal Quantitative Ultrasound, and Bone Mineral Density in Men. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa179.	0.1	6
11	Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 291-297.	3.1	15
12	Bone density, microarchitecture and tissue quality after 1 year of treatment with dolutegravir/abacavir/lamivudine. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2998-3003.	1.3	5
13	Functional Assessment of Coding and Regulatory Variants From the <i>DKK1</i> Locus. <i>JBMR Plus</i> , 2020, 4, e10423.	1.3	5
14	Normative Data for Impact Microindentation for Australian Men: Cross-sectional Data From the Geelong Osteoporosis Study. <i>JBMR Plus</i> , 2020, 4, e10384.	1.3	4
15	Oral Bisphosphonate Use and All-cause Mortality in Patients With Moderate-to-Severe (Grade 3-5D) Chronic Kidney Disease: A Population-based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 894-900.	3.1	8
16	Bone material strength index is associated with prior fracture in men with and without moderate chronic kidney disease. <i>Bone</i> , 2020, 133, 115241.	1.4	14
17	Bone tissue quality in patients with monoclonal gammopathy of uncertain significance. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 563-569.	1.3	5
18	Effect of the Tumor Suppressor miR-320a on Viability and Functionality of Human Osteosarcoma Cell Lines Compared to Primary Osteoblasts. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2852.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090966.	1.4	10
20	Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 820-832.	3.1	46
21	Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1375-1389.	1.4	53
22	Associations Between Bone Impact Microindentation and Clinical Risk Factors for Fracture. <i>Endocrinology</i> , 2019, 160, 2143-2150.	1.4	13
23	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. <i>Advances in Therapy</i> , 2019, 36, 2811-2824.	1.3	60
24	Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 53-60.	1.1	14
25	Functional characterization of the C7ORF76 genomic region, a prominent GWAS signal for osteoporosis in 7q21.3. <i>Bone</i> , 2019, 123, 39-47.	1.4	12
26	Proof of Concept on Functionality Improvement of Mesenchymal Stem-Cells, in Postmenopausal Osteoporotic Women Treated with Teriparatide (PTH1-34), After Suffering Atypical Fractures. <i>Calcified Tissue International</i> , 2019, 104, 631-640.	1.5	5
27	Validation of fragility fractures in primary care electronic medical records: A population-based study. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, e1-e4.	0.2	0
28	Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis. <i>Bone</i> , 2019, 120, 1-8.	1.4	75
29	Validation of fragility fractures in primary care electronic medical records: A population-based study. <i>Reumatología Clínica</i> , 2019, 15, e1-e4.	0.2	14
30	Circulating miR-103a-3p and miR-660-5p are associated with bone parameters in patients with controlled acromegaly. <i>Endocrine Connections</i> , 2019, 8, 39-49.	0.8	15
31	Differential Mortality and the Excess Rates of Hip Fracture Associated With Type 2 Diabetes: Accounting for Competing Risks in Fracture Prediction Matters. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1417-1421.	3.1	27
32	Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate. <i>Aids</i> , 2018, 32, 913-920.	1.0	26
33	Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1397-1406.	3.1	144
34	Cortical and Trabecular Bone Analysis of Patients With High Bone Mass From the Barcelona Osteoporosis Cohort Using 3-Dimensional Dual-Energy X-ray Absorptiometry: A Case-Control Study. <i>Journal of Clinical Densitometry</i> , 2018, 21, 480-484.	0.5	1
35	Expression profiling of microRNAs in human bone tissue from postmenopausal women. <i>Human Cell</i> , 2018, 31, 33-41.	1.2	15
36	Advances in the evaluation of bone health in kidney transplant patients. <i>Nefrología</i> , 2018, 38, 27-33.	0.2	2

#	ARTICLE	IF	CITATIONS
37	Avances en la valoración de la salud ósea en el trasplantado renal. <i>Nefrologia</i> , 2018, 38, 27-33.	0.2	3
38	Feasibility and tolerability of bone impact microindentation testing: a cross-sectional, population-based study in Australia. <i>BMJ Open</i> , 2018, 8, e023959.	0.8	20
39	Pro-osteoporotic miR-320a impairs osteoblast function and induces oxidative stress. <i>PLoS ONE</i> , 2018, 13, e0208131.	1.1	20
40	Functional Characterization of a GGPPS Variant Identified in Atypical Femoral Fracture Patients and Delineation of the Role of GGPPS in Bone-Relevant Cell Types. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 2091-2098.	3.1	21
41	Bone health evaluation one year after aromatase inhibitors completion. <i>Bone</i> , 2018, 117, 54-59.	1.4	9
42	Fracture risk in type 2 diabetic patients: A clinical prediction tool based on a large population-based cohort. <i>PLoS ONE</i> , 2018, 13, e0203533.	1.1	7
43	Common and rare variants of WNT16, DKK1 and SOST and their relationship with bone mineral density. <i>Scientific Reports</i> , 2018, 8, 10951.	1.6	14
44	Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women. <i>Maturitas</i> , 2018, 116, 83-88.	1.0	4
45	Maintenance low dose systemic glucocorticoids have limited impact on bone strength and mineral density among incident renal allograft recipients: A pilot prospective cohort study. <i>Bone</i> , 2018, 116, 290-294.	1.4	9
46	Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1575-1581.	3.1	13
47	Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir/Emtricitabine or Abacavir/Lamivudine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 322-327.	0.9	26
48	GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates. <i>New England Journal of Medicine</i> , 2017, 376, 1794-1795.	13.9	50
49	SNPs in bone-related miRNAs are associated with the osteoporotic phenotype. <i>Scientific Reports</i> , 2017, 7, 516.	1.6	17
50	Presence of pyrophosphate in bone from an atypical femoral fracture site: A case report. <i>Bone Reports</i> , 2017, 6, 81-86.	0.2	9
51	Bone Density, Microarchitecture, and Tissue Quality Long-term After Kidney Transplant. <i>Transplantation</i> , 2017, 101, 1290-1294.	0.5	31
52	Insulin use and Excess Fracture Risk in Patients with Type 2 Diabetes: A Propensity-Matched cohort analysis. <i>Scientific Reports</i> , 2017, 7, 3781.	1.6	44
53	Fracture during oral bisphosphonate therapy is associated with deteriorated bone material strength index. <i>Bone</i> , 2017, 103, 64-69.	1.4	19
54	Clinical experience with microindentation in vivo in humans. <i>Bone</i> , 2017, 95, 175-182.	1.4	30

#	ARTICLE	IF	CITATIONS
55	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 3-10.	3.1	127
56	Octodon degus, a new model to study the agonist and plexus-induced response in the urinary bladder. <i>Journal of Physiology and Biochemistry</i> , 2017, 73, 77-87.	1.3	1
57	Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection. <i>AIDS Research and Treatment</i> , 2016, 2016, 1-8.	0.3	9
58	Brief Report: HIV Infection Is Associated With Worse Bone Material Properties, Independently of Bone Mineral Density. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 314-318.	0.9	35
59	Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1466-1472.	3.1	29
60	Obesity and the Relative Risk of Knee Replacement Surgery in Patients With Knee Osteoarthritis: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 817-825.	2.9	61
61	Real-Life and RCT Participants: Alendronate Users Versus FITs™ Trial Eligibility Criterion. <i>Calcified Tissue International</i> , 2016, 99, 243-249.	1.5	29
62	MiRNA profiling of whole trabecular bone: identification of osteoporosis-related changes in MiRNAs in human hip bones. <i>BMC Medical Genomics</i> , 2016, 8, 75.	0.7	67
63	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2016, 28, 1-16.	1.4	22
64	Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 234-244.	3.1	16
65	AI-related BMD variation in actual practice conditions: A prospective cohort study. <i>Endocrine-Related Cancer</i> , 2016, 23, 303-312.	1.6	4
66	Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies. <i>Calcified Tissue International</i> , 2016, 98, 359-369.	1.5	27
67	Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1651-1656.	3.1	78
68	Are the High Hip Fracture Rates Among Norwegian Women Explained by Impaired Bone Material Properties?. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1784-1789.	3.1	42
69	Socioeconomic status and its association with the risk of developing hip fractures: A region-wide ecological study. <i>Bone</i> , 2015, 73, 127-131.	1.4	27
70	Erratum to "The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)" [Maturitas 79 (2014) 122-132]. <i>Maturitas</i> , 2015, 80, 337.	1.0	2
71	Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment. <i>Current Medical Research and Opinion</i> , 2015, 31, 767-777.	0.9	13
72	Increased hip fracture and mortality in chronic kidney disease individuals: The importance of competing risks. <i>Bone</i> , 2015, 73, 154-159.	1.4	31

#	ARTICLE	IF	CITATIONS
73	Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2104-2107.	1.3	25
74	Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis. <i>Maturitas</i> , 2015, 82, 402-410.	1.0	7
75	Tuberculosis: Plasma levels of vitamin D and its relation with infection and disease. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 111-114.	0.1	3
76	Genetic Analysis of High Bone Mass Cases from the BARCOS Cohort of Spanish Postmenopausal Women. <i>PLoS ONE</i> , 2014, 9, e94607.	1.1	14
77	Current and future treatments of secondary osteoporosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 885-894.	2.2	13
78	Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>Journal of Bone and Mineral Research</i> , 2014, 29, 260-267.	3.1	47
79	Predictors of Fracture While on Treatment With Oral Bisphosphonates: A Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 268-274.	3.1	48
80	Ankylosing Spondylitis Is Associated With an Increased Risk of Vertebral and Nonvertebral Clinical Fractures: A Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1770-1776.	3.1	70
81	Relationship of Weight, Height, and Body Mass Index With Fracture Risk at Different Sites in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>Journal of Bone and Mineral Research</i> , 2014, 29, 487-493.	3.1	192
82	Empirically Based Composite Fracture Prediction Model From the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 817-826.	1.8	14
83	Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review. <i>Bone</i> , 2014, 58, 126-135.	1.4	172
84	Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1659-1664.	0.5	559
85	The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Maturitas</i> , 2014, 79, 122-132.	1.0	213
86	Obesity, Health-Care Utilization, and Health-Related Quality of Life After Fracture in Postmenopausal Women: Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>Calcified Tissue International</i> , 2014, 94, 223-231.	1.5	36
87	Romosozumab in Postmenopausal Women with Low Bone Mineral Density. <i>New England Journal of Medicine</i> , 2014, 370, 412-420.	13.9	981
88	Relationship Between Mortality and BMI After Fracture: A Population-Based Study of Men and Women Aged ≥40 Years. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1737-1744.	3.1	45
89	A Meta-Analysis of the Association of Fracture Risk and Body Mass Index in Women. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 223-233.	3.1	388
90	Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 385-395.	1.1	37

#	ARTICLE	IF	CITATIONS
91	Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 162-168.	3.1	130
92	The association between fracture site and obesity in men: A population-Based cohort study. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1771-1777.	3.1	103
93	Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength. <i>Journal of Medical Devices, Transactions of the ASME</i> , 2013, 7, 410051-410056.	0.4	59
94	Analyses of <i>RANK</i> and <i>RANKL</i> in the Post-GWAS Context: Functional Evidence of Vitamin D Stimulation Through a <i>RANKL</i> Distal Region. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2550-2560.	3.1	11
95	HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: A population-based cohort study. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1259-1263.	3.1	115
96	An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 911-917.	0.5	76
97	When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>PLoS ONE</i> , 2013, 8, e83306.	1.1	63
98	Patterns of Anti-Osteoporosis Medication Use among Women at High Risk of Fracture: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>PLoS ONE</i> , 2013, 8, e82840.	1.1	6
99	Teriparatide for Glucocorticoid-induced Osteoporosis. <i>Journal of Rheumatology</i> , 2012, 39, 461-462.	1.0	1
100	Is there a future for selective estrogen-receptor modulators in osteoporosis?. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 55-59.	1.2	3
101	Probability of fractures predicted by FRAX [®] and observed incidence in the Spanish ECOSAP Study cohort. <i>Bone</i> , 2012, 50, 373-377.	1.4	76
102	Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>Bone</i> , 2012, 50, 1288-1293.	1.4	129
103	Characteristics associated with anti-osteoporosis medication use: Data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort. <i>Bone</i> , 2012, 51, 975-980.	1.4	36
104	The association between fracture and obesity is site-dependent: A population-based study in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 294-300.	3.1	261
105	Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 645-653.	3.1	143
106	Risk factors for prediction of inadequate response to antiresorptives. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 817-824.	3.1	63
107	<i>COL1A1</i> haplotypes and hip fracture. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 950-953.	3.1	17
108	Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1159-1167.	1.1	34

#	ARTICLE	IF	CITATIONS
109	Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. <i>Breast</i> , 2012, 21, 95-101.	0.9	40
110	Official Positions for FRAX® Bone Mineral Density and FRAX® Simplification. <i>Journal of Clinical Densitometry</i> , 2011, 14, 226-236.	0.5	45
111	Obesity Is Not Protective against Fracture in Postmenopausal Women: GLOW. <i>American Journal of Medicine</i> , 2011, 124, 1043-1050.	0.6	446
112	Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>Bone</i> , 2011, 49, 493-498.	1.4	78
113	Comparison of the Effects of Ossein-Hydroxyapatite Complex and Calcium Carbonate on Bone Metabolism in Women with Senile Osteoporosis. <i>Clinical Drug Investigation</i> , 2011, 31, 817-824.	1.1	11
114	Calcium Citrate and Vitamin D in the Treatment of Osteoporosis. <i>Clinical Drug Investigation</i> , 2011, 31, 285-298.	1.1	26
115	Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 869-878.	1.1	80
116	Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis. <i>Calcified Tissue International</i> , 2011, 89, 91-104.	1.5	170
117	Functional relevance of the BMD-associated polymorphism rs312009: Novel Involvement of RUNX2 in <i>LRP5</i> transcriptional regulation. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1133-1144.	3.1	14
118	Predicting fractures in an international cohort using risk factor algorithms without BMD. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2770-2777.	3.1	58
119	Analysis of Three Functional Polymorphisms in Relation to Osteoporosis Phenotypes: Replication in a Spanish Cohort. <i>Calcified Tissue International</i> , 2010, 87, 14-24.	1.5	25
120	Baseline observations from the POSSIBLE EU study: characteristics of postmenopausal women receiving bone loss medications. <i>Archives of Osteoporosis</i> , 2010, 5, 61-72.	1.0	16
121	Microindentation for in vivo measurement of bone tissue mechanical properties in humans. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 1877-1885.	3.1	237
122	Effect of IL-1 β , PGE ₂ , and TGF β 1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts. <i>Journal of Cellular Biochemistry</i> , 2010, 110, 304-310.	1.2	27
123	Impact of Prevalent Fractures on Quality of Life: Baseline Results From the Global Longitudinal Study of Osteoporosis in Women. <i>Mayo Clinic Proceedings</i> , 2010, 85, 806-813.	1.4	159
124	Bone mass loss after sleeve gastrectomy: A prospective comparative study with gastric bypass. <i>Cirug�a Espa�ola (English Edition)</i> , 2010, 88, 103-109.	0.1	36
125	Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. <i>Maturitas</i> , 2010, 66, 291-297.	1.0	50
126	Prevalence of vertebral fracture in postmenopausal women with lumbar osteopenia using MorphoXpressSR (OSTEOXPRESS Study). <i>Aging Clinical and Experimental Research</i> , 2010, 22, 419-426.	1.4	10

#	ARTICLE	IF	CITATIONS
127	A Haplotype-Based Analysis of the <i>LRP5</i> Gene in Relation to Osteoporosis Phenotypes in Spanish Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1954-1963.	3.1	18
128	Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. <i>Journal of Cellular Biochemistry</i> , 2007, 101, 1430-1438.	1.2	80
129	Promoter 2 -1025 T/C Polymorphism in the RUNX2 Gene Is Associated with Femoral Neck BMD in Spanish Postmenopausal Women. <i>Calcified Tissue International</i> , 2007, 81, 327-332.	1.5	32
130	Influence of the Bsm1 polymorphism of the vitamin D receptor gene on rheumatoid arthritis clinical activity. <i>Journal of Rheumatology</i> , 2007, 34, 1823-6.	1.0	29
131	A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women. <i>Bone</i> , 2006, 38, 738-743.	1.4	27
132	Large-Scale Evidence for the Effect of the COL1A1 Sp1 Polymorphism on Osteoporosis Outcomes: The GENOMOS Study. <i>PLoS Medicine</i> , 2006, 3, e90.	3.9	160
133	Selective estrogen receptor modulators (SERMS). <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2006, 50, 720-734.	1.3	21
134	The Association between Common Vitamin D Receptor Gene Variations and Osteoporosis: A Participant-Level Meta-Analysis. <i>Annals of Internal Medicine</i> , 2006, 145, 255.	2.0	219
135	Relationship Between Bone Quantitative Ultrasound and Fractures: A Meta-Analysis. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 1126-1135.	3.1	130
136	Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. <i>Osteoporosis International</i> , 2006, 17, 1-7.	1.3	39
137	Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. <i>Osteoporosis International</i> , 2006, 17, 313-316.	1.3	94
138	Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1514-1524.	3.1	206
139	Functional analysis of the I.3, I.6, pII and I.4 promoters of CYP19 (aromatase) gene in human osteoblasts and their role in vitamin D and dexamethasone stimulation. <i>European Journal of Endocrinology</i> , 2005, 153, 981-988.	1.9	34
140	In vitro functional assay of alleles and haplotypes of two -promoter SNPs. <i>Bone</i> , 2005, 36, 902-908.	1.4	36
141	Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography. <i>Bone</i> , 2004, 35, 1164-1168.	1.4	25
142	Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk. <i>Journal of Bone and Mineral Research</i> , 2003, 19, 394-401.	3.1	190
143	Evaluation of Calcaneal Quantitative Ultrasound in a Primary Care Setting as a Screening Tool for Osteoporosis in Postmenopausal Women. <i>Journal of Clinical Densitometry</i> , 2003, 6, 237-245.	0.5	42
144	Regulation of CYP19 gene expression in primary human osteoblasts: effects of vitamin D and other treatments. <i>European Journal of Endocrinology</i> , 2003, 148, 519-526.	1.9	58

#	ARTICLE	IF	CITATIONS
145	Bone metabolism and histomorphometric changes in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2002, 31, 285-290.	0.6	15
146	Bisphosphonates. <i>Maturitas</i> , 2002, 43, 19-26.	1.0	18
147	Ataxic form of central pontine myelinolysis. <i>Lancet Neurology</i> , The, 2002, 1, 517-518.	4.9	19
148	Two New Single-Nucleotide Polymorphisms in the COL1A1 Upstream Regulatory Region and Their Relationship to Bone Mineral Density. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 384-393.	3.1	91
149	Measuring quality of life in women with vertebral fractures due to osteoporosis: a comparison of the OQLQ and QUALEFFO. <i>Quality of Life Research</i> , 2001, 10, 307-317.	1.5	42